Effect of Benaglutide on Gut Microbiota and Fecal Metabolites in Patients with Type 2 Diabetes Mellitus

Overview

Journal Diabetes Metab Syndr Obes

Publisher Dove Medical Press

Specialty Endocrinology

Date 2023 Aug 14

PMID 37577040

Authors

Chen-Yu Han

Xiao-Mei Ye

Jia-Ping Lu

Hai-Ying Jin

Ping Wang

Wei-Wei Xu

Min Zhang

Affiliations

Soon will be listed here.

Abstract

Objective: Benaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) that has been approved in the treatment of type 2 diabetes mellitus (T2DM). It is known to lead to significant weight loss, and it is hypothesized that changes in gut microbiota may play a significant role in such weight loss. However, it is unclear how gut microbiota and metabolites change as a result of benaglutide treatment.

Methods: Healthy participants and patients with T2DM were included in this study. They received differentiated treatments, and stool specimens were collected separately. These stool specimens were subjected to 16S ribosomal RNA amplicon and metagenomic sequencing to create fecal metabolomic profiles. The diversity of gut microbiota and metabolic products in the stools of each participant was analyzed.

Results: The data showed that was abundant in the gut microbiota of the control group, which was entirely made up of healthy individuals; however, it showed a statistically significant decrease in patients with T2DM treated with metformin alone, while no significant decrease was observed in patients treated with metformin combined with benaglutide. A metagenomic analysis revealed that benaglutide could improve the fecal microbiota diversity in patients with T2DM. Furthermore, there was a statistically significant correlation between the changes in the metabolites of patients with T2DM and the changes in their gut microbiota (including ) after treatment with metformin and benaglutide.

Conclusion: These findings suggest that the weight-reducing effect of benaglutide is attributed to its ability to normalize the gut microbiota of patients with T2DM, particularly by increasing the abundance of .

Citing Articles

Double-blinded, randomized clinical trial of Gegen Qinlian decoction pinpoints as key gut bacteria in alleviating hyperglycemia.

Gao Z, Zhang W, He L, Wang H, Li Y, Jiang X Precis Clin Med. 2024; 7(1):pbae003.

PMID: 38495337 PMC: 10941319. DOI: 10.1093/pcmedi/pbae003.

References

Murphy R, Tsai P, Jullig M, Liu A, Plank L, Booth M . Differential Changes in Gut Microbiota After Gastric Bypass and Sleeve Gastrectomy Bariatric Surgery Vary According to Diabetes Remission. Obes Surg. 2016; 27(4):917-925. DOI: 10.1007/s11695-016-2399-2. View

Furet J, Kong L, Tap J, Poitou C, Basdevant A, Bouillot J . Differential adaptation of human gut microbiota to bariatric surgery-induced weight loss: links with metabolic and low-grade inflammation markers. Diabetes. 2010; 59(12):3049-57. PMC: 2992765. DOI: 10.2337/db10-0253. View

Tolhurst G, Heffron H, Lam Y, Parker H, Habib A, Diakogiannaki E . Short-chain fatty acids stimulate glucagon-like peptide-1 secretion via the G-protein-coupled receptor FFAR2. Diabetes. 2011; 61(2):364-71. PMC: 3266401. DOI: 10.2337/db11-1019. View

Rahat-Rozenbloom S, Fernandes J, Gloor G, Wolever T . Evidence for greater production of colonic short-chain fatty acids in overweight than lean humans. Int J Obes (Lond). 2014; 38(12):1525-31. PMC: 3970979. DOI: 10.1038/ijo.2014.46. View

Brennan C, Garrett W . Gut Microbiota, Inflammation, and Colorectal Cancer. Annu Rev Microbiol. 2016; 70:395-411. PMC: 5541233. DOI: 10.1146/annurev-micro-102215-095513. View

Vilsboll T, Christensen M, Junker A, Knop F, Gluud L . Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials. BMJ. 2012; 344:d7771. PMC: 3256253. DOI: 10.1136/bmj.d7771. View

Graessler J, Qin Y, Zhong H, Zhang J, Licinio J, Wong M . Metagenomic sequencing of the human gut microbiome before and after bariatric surgery in obese patients with type 2 diabetes: correlation with inflammatory and metabolic parameters. Pharmacogenomics J. 2012; 13(6):514-22. DOI: 10.1038/tpj.2012.43. View

Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F . A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012; 490(7418):55-60. DOI: 10.1038/nature11450. View

Salamon D, Sroka-Oleksiak A, Kapusta P, Szopa M, Mrozinska S, Ludwig-Slomczynska A . Characteristics of gut microbiota in adult patients with type 1 and type 2 diabetes based on next‑generation sequencing of the 16S rRNA gene fragment. Pol Arch Intern Med. 2018; 128(6):336-343. DOI: 10.20452/pamw.4246. View

10.

Nohr M, Pedersen M, Gille A, Egerod K, Engelstoft M, Husted A . GPR41/FFAR3 and GPR43/FFAR2 as cosensors for short-chain fatty acids in enteroendocrine cells vs FFAR3 in enteric neurons and FFAR2 in enteric leukocytes. Endocrinology. 2013; 154(10):3552-64. DOI: 10.1210/en.2013-1142. View

11.

Maskarinec G, Raquinio P, Kristal B, Setiawan V, Wilkens L, Franke A . The gut microbiome and type 2 diabetes status in the Multiethnic Cohort. PLoS One. 2021; 16(6):e0250855. PMC: 8221508. DOI: 10.1371/journal.pone.0250855. View

12.

de la Cuesta-Zuluaga J, Mueller N, Alvarez-Quintero R, Velasquez-Mejia E, Sierra J, Corrales-Agudelo V . Higher Fecal Short-Chain Fatty Acid Levels Are Associated with Gut Microbiome Dysbiosis, Obesity, Hypertension and Cardiometabolic Disease Risk Factors. Nutrients. 2018; 11(1). PMC: 6356834. DOI: 10.3390/nu11010051. View

13.

Aktas G, Kocak M, Bilgin S, Atak B, Duman T, Kurtkulagi O . Uric acid to HDL cholesterol ratio is a strong predictor of diabetic control in men with type 2 diabetes mellitus. Aging Male. 2019; 23(5):1098-1102. DOI: 10.1080/13685538.2019.1678126. View

14.

Zhang Y, Zhou C, Li X, Yang M, Tao L, Zheng X . Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study. Obes Sci Pract. 2019; 5(4):366-375. PMC: 6700512. DOI: 10.1002/osp4.342. View

15.

Sililas P, Huang L, Thonusin C, Luewan S, Chattipakorn N, Chattipakorn S . Association between Gut Microbiota and Development of Gestational Diabetes Mellitus. Microorganisms. 2021; 9(8). PMC: 8400162. DOI: 10.3390/microorganisms9081686. View

16.

Remely M, Aumueller E, Merold C, Dworzak S, Hippe B, Zanner J . Effects of short chain fatty acid producing bacteria on epigenetic regulation of FFAR3 in type 2 diabetes and obesity. Gene. 2013; 537(1):85-92. DOI: 10.1016/j.gene.2013.11.081. View

17.

Que Y, Cao M, He J, Zhang Q, Chen Q, Yan C . Gut Bacterial Characteristics of Patients With Type 2 Diabetes Mellitus and the Application Potential. Front Immunol. 2021; 12:722206. PMC: 8415158. DOI: 10.3389/fimmu.2021.722206. View

18.

Lippert K, Kedenko L, Antonielli L, Kedenko I, Gemeier C, Leitner M . Gut microbiota dysbiosis associated with glucose metabolism disorders and the metabolic syndrome in older adults. Benef Microbes. 2017; 8(4):545-556. DOI: 10.3920/BM2016.0184. View

19.

Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C . Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One. 2013; 8(8):e71108. PMC: 3754967. DOI: 10.1371/journal.pone.0071108. View

20.

van Bloemendaal L, Ten Kulve J, la Fleur S, IJzerman R, Diamant M . Effects of glucagon-like peptide 1 on appetite and body weight: focus on the CNS. J Endocrinol. 2013; 221(1):T1-16. DOI: 10.1530/JOE-13-0414. View